Mylan Looks To Expedite Biosimilar Humira in EU Through Kyowa Deal

Mylan has acquired commercial rights in Europe to Kyowa Hakko Kirin's biosimilar adalimumab, paving the way to an early market entry through the product, which could be approved in the second half of this year. But might there be a shift in the commercialization outlook for its partnered adalimumab with Biocon?

3d render of Europe map Earth globe
MYLAN GAINS EU RIGHTS TO BIOSIMILAR HUMIRA

Mylan NV is to jump start its plans for biosimilar adalimumab in Europe through an alliance with Japan’s Fujifilm Kyowa Kirin Biologics Co. Ltd. (FKB), in a move that may have an impact on Mylan's existing biosimilars alliance with Indian firm Biocon Ltd..

Mylan has been granted an exclusive license to commercialize in Europe the Japanese company’s FKB327, a biosimilar version of

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from India

More from Focus On Asia